olmutinib
Ligand Summary
Olmutinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for the treatment of non-small cell lung cancer (NSCLC). Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymatic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.
UNII: CHL9B67L95
PubChem: 54758501
ChEMBL: CHEMBL3786343
DrugCentral: 5210
LyCHI: HN5ARD4YQZDD
Target Activities
6 Activities
Items per page:
1 – 6 of 6
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | INHIBITOR | |||||